Premium
Zonisamide in the treatment of bulimia nervosa: An open‐label, pilot, prospective study
Author(s) -
Guerdjikova Anna I.,
Blom Thomas J.,
Martens Brian E.,
Keck Paul E.,
McElroy Susan L.
Publication year - 2013
Publication title -
international journal of eating disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.785
H-Index - 138
eISSN - 1098-108X
pISSN - 0276-3478
DOI - 10.1002/eat.22159
Subject(s) - zonisamide , bulimia nervosa , binge eating , discontinuation , psychology , open label , anorexia nervosa , psychiatry , eating disorders , medicine , clinical trial , topiramate , epilepsy
Objective To assess preliminarily the effectiveness of zonisamide in bulimia nervosa. Method This was an open‐label, prospective, 12‐week, flexible dose study of zonisamide in bulimia nervosa. The primary outcome was binge‐purge episode frequency. Results Twelve individuals received zonisamide, 10 completed at least one post‐baseline evaluation, and six completed the study. Mean dose at endpoint was 420 (SD = 215) mg/day. Zonisamide was associated with significant reductions in frequency of binge‐purge episodes and binge‐purge days as well as measures of binge eating behavior, purging behavior, clinical severity, obsessive‐compulsive features, and depressive symptoms. Weight was unchanged. Discussion In this open‐label trial, zonisamide was effective in bulimia nervosa, but associated with a high discontinuation rate. © 2013 Wiley Periodicals, Inc. (Int J Eat Disord 2013; 46:747–750)